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RESEARCH ARTICLE
Evaluation of the efficacy of a 
commercial inactivated genogroup 2b-based 
porcine epidemic diarrhea virus (PEDV) vaccine 
and experimental live genogroup 1b exposure 
against 2b challenge
Tanja Opriessnig1,2*, Priscilla F. Gerber1,3, Huigang Shen2, Alessandra Marnie M. G. de Castro2,4, 
Jianqiang Zhang2, Qi Chen2 and Patrick Halbur2
Abstract 
Porcine epidemic diarrhea virus strains from the G1b cluster are considered less pathogenic compared to the G2b 
cluster. The aim of this study was to compare the ability of G1b-based live virus exposure against use of a commercial 
G2b–based inactivated vaccine to protect growing pigs against G2b challenge. Thirty-nine PEDV naïve pigs were 
randomly divided into five groups: EXP-IM-1b (intramuscular G1b exposure; G2b challenge), EXP-ORAL-1b (oral G1b 
exposure; G2b challenge), VAC-IM-2b (intramuscular commercial inactivated G2b vaccination; G2b challenge), POS-
CONTROL (sham-vaccination; G2b challenge) and NEG-CONTROL (sham-vaccination; sham-challenge). Pigs were 
vaccinated/exposed at 3 weeks of age (day post-vaccination 0, dpv 0), VAC-IM-2b pigs were revaccinated at dpv 14, 
and the pigs were challenged at dpv 28. Among all groups, VAC-IM-2b pigs had significantly higher anti-PEDV IgG 
levels on dpv 21 and 28 while EXP-ORAL-1b pigs had significantly higher anti-PEDV IgA levels on dpv 14, 21, 28 and 
35. EXP-ORAL-1b also had detectable IgA in feces. Intramuscular PEDV exposure did not result in a detectable anti-
body response in EXP-IM-1b pigs. The fecal PEDV RNA levels in VAC-IM-2b pigs were significantly lower 5–7 days after 
challenge compared to the POS-CONTROL group. Under the study conditions a commercial inactivated G2b-based 
vaccine protected pigs against G2b challenge, as evidenced by reduction of PEDV RNA in feces for 3–4 logs during 
peak shedding and a shorter viral shedding duration. The oral, but not the intramuscular, experimental G1b-based 
live virus exposure induced a high anti-PEDV IgA response prior to challenge, which apparently did not impact PEDV 
shedding compared to POS-CONTROL pigs.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Clinical porcine epidemic diarrhea and its causative 
virus PEDV were discovered in European pigs in the 
1970s [1, 2], spread to Asia during the 1980s and 1990s 
[3], and became endemic in pigs on both continents [2, 
3]. Approximately 10 years ago PEDV re-emerged as an 
important enteric disease of suckling and growing pigs 
[4]. In 2013, PEDV was introduced for the first time to 
North America [5] causing major disease and mortality 
[6].
PEDV can be differentiated into genogroups [7]. On the 
basis of Spike (S) gene sequences, PEDV isolates can be 
divided into G1a, G1b, G2a and G2b [7, 8]. G1a includes 
historic PEDV isolates such as CV777 and attenuated 
variants distributed in Europe and Asia, whilst G1b 
includes the so called S-INDEL strains which can be 
found in Europe, Asia and North America. G2a isolates 
are restricted to Asia whereas G2b isolates are present 
in Asia and the Ukraine [9], and since US introduction 
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in 2013 are widespread in the US and considered the US 
prototype [8, 10]. Differences in pathogenicity between 
representative isolates of different genogroups have been 
demonstrated [10–12], with G2b isolates usually being 
more pathogenic compared to G1b isolates. Partial cross-
protection between PEDV G1b and G2b isolates has been 
demonstrated experimentally [12].
In January 2014 the first conditional licensed PEDV 
vaccine was introduced to the North American pig mar-
ket [13], and today an RNA particle-based vaccine and 
an inactivated PEDV vaccine are available in the US 
to immunize sows against PEDV [13]. While the use of 
these vaccines is often beneficial in previously exposed 
herds, they often fail in naïve herds [14]. One reason for 
the variable vaccine efficacy observed under field con-
ditions may be the usage of inactivated vaccines given 
intramuscularly rather than live virus vaccines given 
orally to induce a strong local enteric immunity. It would 
be risky to use a known pathogenic G2b live vaccine virus 
in a pig population; however, using a less virulent variant 
such as G1b instead may be safe and efficacious.
The objectives of this study were to compare the effi-
cacy of heterologous G1b and homologous G2b based 
vaccines in protecting growing pigs against G2b chal-
lenge. Specifically, an experimental G1b-based live 
vaccine, administered orally or intramuscularly and a 
commercial G2b–based inactivated vaccine administered 
intramuscularly were compared side by side.
Materials and methods
Ethical statement
The experimental protocol was approved by the Iowa 
State University Institutional Animal Care and Use Com-
mittee (Approval Number: 5-14-7804-S).
Animals, housing, and experimental design
Thirty-nine, 2-week-old, colostrum-fed, arbitrarily-
selected, crossbred, PEDV naïve weaned pigs were ran-
domly assigned to one of five rooms and groups, with 
7–8 pigs in each group (Table  1). All groups were fed 
ad  libitum with a balanced, age-appropriate, pelleted 
feed ration. At 3  weeks of age or dpv 0, EXP-IM-1b, 
EXP-ORAL-1b and VAC-IM-2b groups were vaccinated 
with different vaccines and routes as outlined in Table 1, 
whereas POS-CONTROL and NEG-CONTROL pigs 
were sham-vaccinated with saline. VAC-IM-2b pigs were 
revaccinated at 5  weeks of age (dpv 14). At day post-
challenge (dpc) 0 or dpv 28, when the pigs were 7 weeks 
old, they were challenged as shown in Table 1. The POS-
CONTROL group served as a challenge control group 
while the NEG-CONTROL was sham-challenged and 
served as unvaccinated, unchallenged group. Half of the 
pigs in each group were necropsied at dpv 31/dpc 3 and 
the remainder at dpv 42/dpc 14. The experimental design 
and sample collection details are summarized in Figure 1. 
Blood was collected in serum separator tubes on a weekly 
basis (Fisher Scientific, Pittsburgh, PA, USA), centrifuged 
at 3000 × g for 10 min at 4 °C, and the serum was stored 
at −80  °C until testing. Rectal swabs were collected at 
dpv 0, 7, 14, 21 and 28 followed by daily collection until 
dpv 41/dpc 13 using polyester swabs and stored in 5 mL 
plastic tubes containing 1 mL of sterile saline solution at 
−80  °C until testing. Individual fecal samples were col-
lected in 50 mL plastic tubes and frozen immediately at 
−80 °C until testing. 
Vaccination
At 3  weeks of age (dpv 0), the EXP-IM-1b and the 
EXP-ORAL-1b pigs were vaccinated with a G1b (US 
S-INDEL-variant) live PEDV isolate 14-20697 at the 
 7th cell culture passage [10, 15] as indicated in Table  1. 
After cell culture adaption this virus was used to infect 
5-day old pigs previously and had reduced pathogenic-
ity compared to G2b isolates [10]. For the intramuscular 
vaccination, 2 mL of the G1b virus stock with a titer of 
5 × 104 50% tissue culture infectious dose  (TCID50) per 
mL was mixed with 0.4 mL Adjuplex™ vaccine adjuvant 
(Lot Number SLBP5255  V; Sigma-Aldrich, St Louis, 
MO, USA) prior to injection. The same G1b cell culture 
adapted virus stock used in this study has been shown to 
have moderate to severe enteric pathogenicity in 5-day 
old pigs [10]. Each pig in the EXP-IM-1b group received 
2.4 mL intramuscularly into the neck, with a total PEDV 
dose of 1 ×  105  TCID50. For the oral vaccination route, 
each EXP-ORAL-1b pig was administered 10 mL of the 
G1b virus stock with a titer of 6.8 × 103  TCID50 per mL 
by slowly dripping the vaccine into the mouth of each pig 
with a total dose of 6.8 × 104  TCID50. Adjuvant was not 
used for the oral vaccination route. Pigs in the VAC-IM-
2b group were vaccinated intramuscularly with 2 mL of 
a commercial conditionally-licensed inactivated PEDV 
vaccine based on a G2b strain (Zoetis; Serial Number 
117962) into the right neck. The VAC-IM-2b group was 
revaccinated 2  weeks later (dpv 14) with another 2  mL 
of the vaccine as recommended by the manufacturer. 
The POS-CONTROL group was sham-vaccinated intra-
muscularly in the neck with 2.4 mL saline and the NEG-
CONTROL group was sham-vaccinated orally with 
10 mL saline (Table 1).
Challenge
The  8th passage of virulent PEDV G2b strain 13-19338E 
[10, 16] was grown to a final titer of 6.8 ×  104  TCID50 
per mL. At 7 weeks of age, EXP-IM-1b, EXP-ORAL-1b, 
VAC-IM-2b and POS-CONTROL pigs (Table 1) received 
10 mL of the PEDV G2b challenge virus stock orally by 
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slowly dripping the inoculum into the mouth with a total 
dose of 6.8 ×  105  TCID50. Pigs in the NEG-CONTROL 
group were sham-inoculated with 10 mL saline orally.
Average daily weight gain and clinical observations
All pigs were weighed at dpv 0, at dpv 28/dpc 0 and at 
dpv 42/dpc 14 (Figure 1). The average daily gain (ADG) 
from dpv 0 (vaccination 1) to dpv 42/dpc 14 (necropsy 2) 
was calculated. After PEDV challenge the fecal consist-
ency was scored for each pig daily, ranging from 0 to 3 
with 0 = solid, 1 = semisolid, 2 = pasty, and 3 = liquid. 
All pigs were examined daily for other signs of illness 
including lethargy, respiratory disease, inappetence and 
lameness.
Serology
All serum samples were tested for the presence of PEDV 
IgG and IgA antibodies by an in-house PEDV G2b S1 
protein based indirect ELISA [17, 18]. For IgG detection, 
a sample-to-positive (S/P) ratio of > 0.2 was considered 
positive, between 0.14 and 0.2 as suspect, and < 0.14 as 
negative. For the IgA ELISA an S/P ratio above or equal 
to 0.14 was considered positive. In addition, fecal samples 
collected at dpv 0, dpv 28, and at necropsy at dpv 31/dpc 
3 or dpv 42/dpc 14 were also tested for presence of PEDV 
IgA antibodies [18]. Modifications for this assay included 
that samples were diluted 1:2 and the secondary anti-
body was diluted 1:2000. The positive cutoff for this assay 
was S/P ratio equal or greater than 0.14. Serum samples 
at dpv 28 were titrated for anti-PEDV virus neutralizing 
antibodies by an immunofluorescence assay as previously 
described [15]. Serum was diluted two-fold starting from 
1:20 to 1:1280. Titers were given as the reciprocal of the 
last dilution giving a positive result.
RNA extraction, detection and quantification of PEDV RNA
Total nucleic acids were extracted from all rectal swabs 
using the MagMax™ Pathogen RNA Kit (Applied Bio-
systems, Life Technologies, Carlsbad, CA, USA) on an 
automated nucleic acid extraction system (Thermo Sci-
entific  Kingfisher® Flex, Thermo Fisher Scientific, Pitts-
burgh, PA, USA) according to the instructions of the 
manufacturer. All RNA extracts were tested for the pres-
ence of PEDV RNA by a quantitative real-time PCR [19]. 
Samples were considered negative when no signal was 
observed within 40 amplification cycles.
Necropsy
Half of the pigs in each group were necropsied at dpv 
31/dpc 3 and the remaining pigs were necropsied at 
dpv 42/dpc 14. The pigs were humanely euthanized by 
intravenous pentobarbital sodium overdose (Fatal  Plus®, 
Figure 1 Experimental design and sample collection. All abbreviations used in Figure 1 are summarized in the black rectangular box. The top 
line indicates the day post PEDV challenge and the corresponding day post vaccination at which the main events including vaccinations, G2b PEDV 
challenge, and necropsies occurred. The pigs were housed in groups of 7–8 and were vaccinated with a live G1b PEDV virus (blue boxes), an inacti-
vated G2b PEDV virus (black boxes) or were sham-vaccinated or sham-challenged (green boxes). Red boxes indicate G2b PEDV challenge.
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Vortech Pharmaceuticals, LTD, Dearborn, MI, USA). 
Gross lesions were assessed by a veterinary patholo-
gist and eight sections of small intestines, three sections 
of large intestines and one section of mesenteric lymph 
node were collected, fixed in 10% neutral-buffered forma-
lin, and routinely processed for histological examination.
Histopathology and immunohistochemistry
Microscopic lesions were evaluated by a veterinary 
pathologist blinded to the treatment groups. Sections of 
small intestines were evaluated for the presence of villus 
atrophy and scored from 0 (none) to 3 (severe). PEDV-
specific antigen was detected by immunohistochemistry 
(IHC) using a monoclonal antibody specific for PEDV 
(BioNote, Hwaseong-si, Gyeonggi-do, Korea) [5, 20]. 
The amount of PEDV antigen was scored by a patholo-
gist blinded to treatment status. Scores ranged from 0 to 
3 with 0 =  no signal, 1 =  1–10% of villous enterocytes 
within the section showing a positive signal, 2 = 11–50% 
of villous enterocytes showing a positive signal, and 
3 = more than 50% of villous enterocytes showing a posi-
tive signal.
Statistical analysis
For data analysis,  JMP® software version 11.0.0 (SAS 
Institute, Cary, NC, USA) was used. Summary statistics 
were calculated for all the groups to assess the overall 
quality of the data set including normality. Statistical 
analysis of the data was performed by one-way analysis 
of variance (ANOVA) for continuous data. A P value of 
less than 0.05 was set as the statistically significant level. 
Pairwise test using Tukey’s adjustment was subsequently 
performed to determine significant group differences. 
Real-time PCR results (copies per mL of fecal swab sus-
pension) were  log10 transformed prior to statistical analy-
sis. The area under the curve (AUC) of viral shedding of 
each animal and the total AUC for each group was calcu-
lated using the log transformed values of the viral loads 
from dpv 29 to 41/dpc 1 to 13. One-way ANOVA and a 
Bonferroni post hoc test were used to compare groups. 
Non-repeated nominal data were assessed using a non-
parametric Kruskal–Wallis one-way ANOVA, and if sig-
nificant, pairwise Wilcoxon tests were used to evaluate 
differences among groups.
Results
Clinical observation and average daily weight gain (ADG)
Clinical signs in the PEDV-infected pigs were limited to 
diarrhea. Three days after vaccination, 4/8 EXP-ORAL-
1b pigs had semisolid feces and 7  days later all pigs in 
this group had pasty feces. None of the pigs in the other 
groups had any fecal consistency changes and all pigs 
remained normal until PEDV challenge. Liquid fecal 
consistency was observed in 4/7 EXP-IM-1b pigs by dpv 
31/dpc 3 and feces remained fluid in the majority of the 
pigs until dpv 35/dpc 7 before becoming pasty-to-solid. 
In the remaining groups individual pigs had liquid feces 
for 1–2 days of duration (data now shown) with no dif-
ferences among groups. The overall ADG is summarized 
in Table  1. There were no significant differences among 
groups.
Anti‑PEDV IgG and neutralizing antibody levels in serum 
samples
All pigs were negative for anti-PEDV IgG antibodies in 
serum samples by ELISA at dpv 0 and NEG-CONTROL 
pigs remained seronegative for the duration of the study. 
Anti-PEDV IgG antibodies were first detected in 2/8 
VAC-IM-PEDV pigs at dpv 7 (Figure  2). By dpv 14, 3/8 
pigs in this group were seropositive and 3/8 were suspect. 
All VAC-IM-2b pigs were anti-PEDV IgG positive by dpv 
21. In the EXP-ORAL-1b group, 6/8 pigs were positive 
for anti-PEDV IgG antibodies by dpv 14, 7/8 were pos-
itive at dpv 21 and at dpv 28, 3/4 pigs were positive by 
dpv 35/dpc 7, and at termination of the study 3/4 were 
positive and 1/4 was suspect (Figure 2). The EXP-IM-1b 
group remained anti-PEDV IgG negative until dpv 35/
dpc 7 at which time all three remaining pigs in this group 
were positive (Figure  2). One of four POS-CONTROL 
pigs seroconverted to PEDV by dpc 7 and all 4 pigs in this 
group were seropositive by dpc 14. Anti-PEDV neutral-
izing antibodies were not detected in the EXP-IM-1b, 
POS-CONTROL and NEG-CONTROL groups at dpv 28. 
Neutralizing antibody titers ranged from 40 to 320 with 
a geometric mean of 89.7 in the EXP-ORAL-1b group, 
and ranged 40–1280 with a geometric mean of 320 in the 
VAC-IM-2b group.
Anti‑PEDV IgA antibody levels in serum and fecal samples
All pigs were negative for anti-PEDV IgA antibodies in 
serum samples by ELISA at dpv 0 and 7 and NEG-CON-
TROL pigs remained seronegative for the duration of 
the study. Anti-PEDV IgA antibodies in serum samples 
were first detected in 8/8 EXP-ORAL-1b pigs at dpv 14 
(Figure  3). One week later at dpv 21, anti-PEDV IgA in 
sera were also detected in 5/8 VAC-IM-2b pigs; however, 
in this group antibody levels decreased, and by dpv 28/
dpc 0 only 1/8 pigs were anti-PEDV IgA positive. IgA 
antibodies against PEDV in the EXP-IM-1b group were 
detected by dpv 35/dpc 7 in 2/3 pigs and by dpv 42/dpc 
14 in 3/3 pigs (Figure  3). One of four POS-CONTROL 
pigs had detectable anti-PEDV IgA antibodies by dpc 7 
and 4/4 pigs were seropositive by dpc 14 (Figure  3). By 
dpv 28/dpc 0, one EXP-ORAL-1b pig had detectable IgA 
levels in feces and by dpv 31/dpc 3 one additional pig in 
this group was positive for PEDV IgA in feces (data not 
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shown). By 14 dpc, PEDV IgA antibodies in feces were 
present in 2/3 EXP-IM-1b pigs, 3/4 EXP-ORAL-1b pigs, 
2/4 POS-CONTROL pigs and 1/4 VAC-IM-2b pigs (data 
not shown).
Prevalence and amount of PEDV RNA in rectal swabs 
and serum samples
All pigs were negative for PEDV RNA in fecal swabs 
on dpv 0 and NEG-CONTROL pigs remained nega-
tive for the duration of the study. After vaccination 
with a live G1b strain, fecal shedding was detected in 
8/8 EXP-ORAL-1b pigs by dpv 7 and in 7/8 pigs by dpv 
14 (Figure  4). In addition, 5/8 EXP-ORAL-1b pigs had 
detectable amounts of PEDV RNA in serum by dpv 7 
(data not shown). On the day of challenge, 1/8 EXP-
ORAL-1b pigs shed low amounts of PEDV in feces. 
PEDV RNA was detected in rectal swabs of 2/8 EXP-
IM-1b pigs by dpv 7; however, PEDV RNA was never 
detected in serum (data not shown). After challenge, 3/7 
EXP-IM-1b pigs shed virus by dpv 29/dpc 1. Viral shed-
ding in rectal swabs was first detected by dpv 30/dpc 2 
in 5/8 EXP-ORAL-1b pigs, in 1/8 VAC-IM-2b pigs and 
in 2/8 POS-CONTROL pigs. Group mean genomic cop-
ies of PEDV RNA in rectal swabs are summarized in 
Figure  5. The average duration of PEDV shedding was 
calculated by adding the number of consecutive PEDV 
PCR positive days of each pig that remained in the study 
until dpv 42/dpc 14 divided by all pigs in a group. The 
average duration of PEDV shedding and the AUC are 
summarized in Table 1.
Gross lesions
At dpv 31/dpc 3, PEDV-infected pigs regardless of vac-
cination status had hyperemic intestines that were fluid-
filled. Specifically, liquid intestinal content was noted in 
3/4 EXP-IM-1b pigs, in 2/4 EXP-ORAL-1b pigs, in 2/4 
VAC-IM-2b pigs and in 1/4 POS-CONTROL pigs. At 
dpv 42/dpc 14, 1/4 POS-CONTROL pigs had fluid filled 
intestines and a dilated colon without remarkable lesions 
in any of the other pigs.
Microscopic lesions and PEDV antigen in tissues
Microscopic lesions were seen in 2/4 EXP-IM-1b pigs, 
1/4 EXP-ORAL-1b pigs, 1/4 VAC-IM-2b pigs and 2/4 
POS-CONTROL pigs which had mild to severe atrophic 
enteritis by dpv 31/dpc 3. There were no lesions in any 
of the other pigs. Five of the six pigs with microscopic 
lesions also had moderate-to-high amounts of PEDV 
Figure 2 Group mean anti-PEDV IgG response in serum samples. The samples were collected at the day of initial vaccination (dpv 0), and 
dpv 7, 14, 21, 28, 35 and 42 and tested by an in house IgG PEDV ELISA. Pigs were exposed to live G1b PEDV at 3 weeks of age (dpv 0) or were vacci-
nated at 3 (dpv 0) and 5 (dpv 14) weeks of age with a commercial inactivated PEDV G2b vaccine. Pigs were challenged with PEDV G2b at 7 weeks of 
age (dpv 28/day post challenge or dpc 0). Data presented as mean group ELISA sample-to-positive (S/P) ratios ± SEM. Significantly different values 
for a dpc are indicated by different superscripts (A,B,C). The significance level was set to P < 0.05. Seropositive pigs/total number of pigs per group for 
groups that contained at least one seropositive pigs can be seen next to the group mean.
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antigen associated with the lesions (two EXP-IM-G1b 
pigs, scores 3 and 3; a EXP-ORAL-G1b pig, score 2; a 
VAC-IM-G2b pig score 3; and a POS-CONTROL pig, 
score 3). There were no significant differences in antigen 
levels or severity of microscopic lesions among groups. 
No microscopic lesions nor PEDV antigen were observed 
at dpv 42/dpc 14.
Discussion
Vaccination strategies to protect against PEDV are chal-
lenging, as the most vulnerable population is suckling 
pigs. Vaccine efficacy studies using pregnant sows are 
difficult and costly. To select novel PEDV vaccine can-
didates and to generate preliminary data, the growing 
pig model has been used [21]. In this study growing pigs 
were used to test and compare the efficacy of live or inac-
tivated vaccines to protect pigs against challenge with a 
highly virulent G2b PEDV isolate.
Pig veterinarians and producers often prefer intramus-
cular administration to assure each pig gets vaccinated 
with the appropriate dose. Intramuscular administration 
is known to induce a systemic immune response [22]. 
In this study, VAC-IM-2b pigs had a strong anti-PEDV 
IgG response in serum which was significantly higher 
compared to EXP-ORAL-1b pigs. This could be due to 
the adjuvant  Amphigen® used in the commercial prod-
uct or due to the booster dose that the VAC-IM-2b pigs 
received. In contrast to live virus exposure, inactivated 
vaccines are almost always given in 2 dose regimens; 
hence in this study the VAC-IM-G2b group received a 
booster dose whereas the EXP-IM-G1b and EXP-ORAL-
G1b pigs did not. In contrast to oral exposure to a live 
virus, pigs vaccinated with the commercial inactivated 
virus had a weak anti-IgA response in serum and no 
anti-PEDV IgA response in feces. This is not surpris-
ing as inactivated vaccines often do not induce effective 
mucosal immunity in naïve pigs whereas oral exposure 
elicits better gut immunity [22]. It has been shown that 
IgA levels in serum correlates with IgA measured in feces 
from experimentally infected piglets [18] and in serum 
and colostrum and milk samples of sows orally immu-
nized [13]. These studies indicate that measuring IgA lev-
els in serum samples may be a marker of protection.
For safety reasons, veterinarians and producers often 
prefer inactivated vaccines. However, for some viruses 
such as porcine reproductive and respiratory syndrome 
Figure 3 Group mean anti-PEDV IgA response in serum samples. The samples were collected at the day of initial vaccination (dpv 0), and dpv 
7, 14, 21, 28, 35 and 42 and tested by an in house IgA PEDV ELISA. Pigs were exposed to live G1b PEDV at 3 weeks of age (dpv 0) or were vaccinated 
at 3 (dpv 0) and 5 (dpv 14) weeks of age with a commercial inactivated PEDV G2b vaccine. Pigs were challenged with PEDV G2b at 7 weeks of age 
(dpv 28/day post challenge or dpc 0). Data presented as mean group ELISA sample-to-positive (S/P) ratios ± SEM. Significantly different values for 
a dpc are indicated by different superscripts (A,B,C). The significance level was set to P < 0.05. Seropositive pigs/total number of pigs per group for 
groups that contained at least one seropositive pigs can be seen next to the group mean.
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virus (PRRSV), it has been shown that inactivated vac-
cines are largely ineffective [23]. PRRSV requires live 
virus to migrate to the lung and replicate at low levels to 
induce protection. Similarly, PEDV may also require local 
activation of the gut-associated mucosal system. In Asia, 
where PEDV vaccines have been available for decades, 
attenuated G1a-based intramuscular vaccines are com-
monly used [4, 24]. We attempted to inject a G1b isolate 
intramuscularly with an adjuvant. Under the study condi-
tions, except for 2/7 EXP-IM-1b pigs with low levels of 
PEDV RNA in rectal swabs at 7 dpv, there was no sign 
of infection in this group based on lack of seroconver-
sion and lack of detectable PEDV RNA in serum or feces. 
The two PEDV RNA positive EXP-IM-1b samples were 
retested and results confirmed (data not shown).
The pigs that were vaccinated intramuscularly with a 
commercial G2b vaccine were protected against homol-
ogous G2b challenge as evidenced by reduction of the 
amount of PEDV RNA in feces by 3–4 logs during peak 
shedding between dpc 5–7 (dpv 33–35) and shortening 
of the duration of viral shedding. Viral titers to deter-
mine infectivity were not determined, but it has been 
shown previously that contact pigs can be infected for 
up to 14 days after initial infection of a seeder pig group 
[25]. In this study a homologous G1b challenge for pigs 
vaccinated with the experimental G1b live vaccine was 
not included due to space and cost reasons. In addition, 
G2b isolates, considered to be more pathogenic com-
pared to G1b isolates [10, 12], appear to be the primary 
cause of clinical disease associated with PEDV under 
field conditions and are more widely distributed com-
pared to G1b isolates. Pigs orally vaccinated with an 
experimental heterologous G1b live vaccine had a ten-
dency for a shortened viral shedding duration; whereas 
pigs vaccinated intramuscularly with an experimental 
heterologous G1b live vaccine were not protected. It has 
been shown that piglets orally inoculated with a virulent 
CV777 strain were fully protected after challenge, while 
protection was not complete in pigs orally inoculated 
with an attenuated CV777 strain [26]. Prior to usage the 
G1b stock was passaged seven times which could have 
resulted in a low degree of attenuation. It is worth not-
ing that pigs orally immunized with the G1b live vaccine 
presented mild diarrhea and shed high levels of virus for 
at least 2 weeks after immunization. This could pose risks 
of infection and potentially more serious clinical signs in 
younger piglets.
Results from studies on cross-protection between 
genogroups have been contradictory. A previous study 
showed that although G1a-based vaccines (CV777 and 
Figure 4 PEDV shedding patterns for all PEDV challenged pigs separated by group over time. For each group a line corresponds to the 
results for a single pig over time and the quantity of virus shed in fecal swabs for all days tested is shown according to the scale on the right side of 
the heat map. The line between day post vaccination (dpv) 28 and day post challenge (dpc) 1 indicates the PEDV G2 challenge with vaccine virus 
on the left side and first possible appearance of challenge virus on the right side.
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DR13 strains) could provide protection against homolo-
gous challenge, they were not protective against con-
temporary Chinese G2b strain YC2014 [27]. It has been 
suggested that sows naturally-infected with a G1b strain 
produce heterologous lactogenic protective immunity 
against G2b strains 7 months after initial infection [28]. 
However, infection of 3–4  day old piglets with G1b 
strain provided variable protection against a G2b chal-
lenge 21–29 days later and the extent of protection was 
shown to be litter-dependent (mortality 0 to 75%) [12]. 
Additionally, the antigen concentration in the commer-
cial  (106–108  TCID50/dose) and experimental  (104–105 
 TCID50/dose) intramuscular vaccines may have contrib-
uted to differences in the protection observed in the cur-
rent study. The dose of experimental vaccine was limited 
by the G1b virus titer achieved after propagation.
Under the conditions of this study, a commercial inac-
tivated G2b-based PEDV vaccine administered intramus-
cularly protected pigs against homologous challenge. In 
contrast, an experimental G1b-based live virus vaccine 
given intramuscularly was not protective. The same virus 
given orally induced a high IgA response but the virus 
shedding pattern after challenge mimicked that of the 
POS-CONTROL group suggesting limited protection. 
This could perhaps indicate that induction of a genotype 
specific humoral and/or cellular immune response may 
be important for PEDV protection.
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